280Bio
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing oral RAS-targeted therapies for cancers driven by KRAS, NRAS, and HRAS mutations.
Oncology
Technology Platform
Platform for developing orally available small molecule inhibitors targeting RAS signaling pathways, including pan-RAS inhibitors and mutation-specific inhibitors against KRAS G12C and other variants.
Opportunities
Large addressable market with RAS mutations in approximately 25% of all cancers; potential for pan-RAS inhibitors to treat broader patient populations than mutation-specific therapies; oral administration offers convenience advantages over injectable competitors.
Risk Factors
Highly competitive landscape with established players in KRAS inhibition; clinical validation needed for pan-RAS approach; potential safety challenges with broad RAS inhibition; dependence on successful clinical trial outcomes and regulatory approvals.
Competitive Landscape
Competes against Amgen (sotorasib), Mirati Therapeutics (adagrasib), and Revolution Medicines in KRAS inhibition space; differentiates through oral pan-RAS inhibitors targeting multiple RAS variants and broader patient populations beyond specific mutations.